Zobrazeno 1 - 10
of 161
pro vyhledávání: '"Tanja D de Gruijl"'
Publikováno v:
Michielon, E, de Gruijl, T D & Gibbs, S 2022, ' From simplicity to complexity in current melanoma models ', Experimental Dermatology, vol. 31, no. 12, pp. 1818-1836 . https://doi.org/10.1111/exd.14675
Despite the recent impressive clinical success of immunotherapy against melanoma, development of primary and adaptive resistance against immune checkpoint inhibitors remains a major issue in a large number of treated patients. This highlights the nee
Autor:
Richard van Hillegersberg, Tom van den Ende, Sybren L. Meijer, Rob H.A. Verhoeven, Max Nieuwdorp, Mark P. G. Dings, Nadia Haj Mohammad, Tanja D. de Gruijl, Nicolien C. de Clercq, H.W.M. van Laarhoven, Jacques J. Bergman, Elisabeth D. Geijsen, Stella Mook, Sandor Schokker, Maarten C.C.M. Hulshof, Nicole C.T. van Grieken, Maarten F. Bijlsma, Bauke Ylstra, Jelle P. Ruurda, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz, Tanya T.D. Soeratram
Publikováno v:
van den Ende, T, Clercq, N D, van Berge Henegouwen, M I, Gisbertz, S S, Geijsen, D, Verhoeven, R, Meijer, S L, Schokker, S, Dings, M, Bergman, J J G H M, Haj Mohammad, N, Ruurda, J P, van Hillegersberg, R, Mook, S, Nieuwdorp, M, de Gruijl, T D, Soeratram, T T D, Ylstra, B, van Grieken, N C T, Bijlsma, M F, Hulshof, M C C M & van Laarhoven, H W 2021, ' Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma : A Single Arm Phase II Feasibility Trial (PERFECT) ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 12, pp. 3351-3359 . https://doi.org/10.1158/1078-0432.CCR-20-4443
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clinical cancer research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clinical cancer research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clin Cancer Res
Purpose: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death ligand-
Autor:
Kim M, van Pul, Jessica C L, Notohardjo, Marieke F, Fransen, Bas D, Koster, Anita G M, Stam, Dafni, Chondronasiou, Sinéad M, Lougheed, Joyce, Bakker, Vinitha, Kandiah, M Petrousjka, van den Tol, Karin, Jooss, Ronald J C L M, Vuylsteke, Alfons J M, van den Eertwegh, Tanja D, de Gruijl
Publikováno v:
Science immunology. 7(73)
Preclinical studies show that locoregional CTLA-4 blockade is equally effective in inducing tumor eradication as systemic delivery, without the added risk of immune-related side effects. This efficacy is related to access of the CTLA-4 blocking antib
Autor:
Arjan W. Griffioen, Peter Timmerman, Ruben S. A. Goedegebuure, Hans J. van der Vliet, Tanja D. de Gruijl, Henk M.W. Verheul, Madelon Q. Wentink
Publikováno v:
Oncologist, 26, 2, pp. e218-e229
Goedegebuure, R S A, Wentink, M Q, van der Vliet, H J, Timmerman, P, Griffioen, A W, de Gruijl, T D & Verheul, H M W 2021, ' A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies ', Oncologist, vol. 26, no. 2, pp. e218-e229 . https://doi.org/10.1002/onco.13576
Oncologist, 26(2), e218-e229. AlphaMed Press
Oncologist, 26, e218-e229
The Oncologist
Goedegebuure, R S A, Wentink, M Q, van der Vliet, H J, Timmerman, P, Griffioen, A W, de Gruijl, T D & Verheul, H M W 2021, ' A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies ', Oncologist, vol. 26, no. 2, pp. e218-e229 . https://doi.org/10.1002/onco.13576
Oncologist, 26(2), e218-e229. AlphaMed Press
Oncologist, 26, e218-e229
The Oncologist
Lessons Learned The novel therapeutic vaccine hVEGF26–104/RFASE was found to be safe and well tolerated in patients with cancer. hVEGF26–104/RFASE failed to induce seroconversion against native hVEGF165 and, accordingly, neither a decrease in cir
Autor:
Nathalie van Leeuwen-Kerkhoff, Shahram Kordasti, Theresia M. Westers, Giovanni A M Povoleri, Tanja D. de Gruijl, Pino J Poddighe, Arjan A. van de Loosdrecht, Jessica A Timms
Publikováno v:
Haematologica, 107(3), 655-667. Ferrata Storti Foundation
van Leeuwen-Kerkhoff, N, Westers, T M, Poddighe, P J, Povoleri, G A M, Timms, J A, Kordasti, S, de Gruijl, T D & van de Loosdrecht, A A 2022, ' Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes ', Haematologica, vol. 107, no. 3, pp. 655-667 . https://doi.org/10.3324/haematol.2020.268136
van Leeuwen-Kerkhoff, N, Westers, T M, Poddighe, P J, Povoleri, G A M, Timms, J A, Kordasti, S, de Gruijl, T D & van de Loosdrecht, A A 2022, ' Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes ', Haematologica, vol. 107, no. 3, pp. 655-667 . https://doi.org/10.3324/haematol.2020.268136
In myelodysplastic syndromes (MDS) the immune system is involved in pathogenesis as well as in disease progression. Dendritic cells (DC) are key players of the immune system by serving as regulators of immune responses. Their function has been scarce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa5391dba937cb802184434c01c08a37
https://research.vumc.nl/en/publications/db725181-9627-4bb8-b6d6-30678dae82ff
https://research.vumc.nl/en/publications/db725181-9627-4bb8-b6d6-30678dae82ff
Autor:
Iris de Weerdt, Tanja D. de Gruijl, Jurjen M Ruben, Hans van Vliet, Mark-David Levin, Lisa A King, Roeland Lameris, Arnon P. Kater, Paul W. H. I. Parren, Renate de Boer, Jan Kloosterman
Publikováno v:
de Weerdt, I, Lameris, R, Ruben, J M, de Boer, R, Kloosterman, J, King, L A, Levin, M-D, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A bispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses toward CD1d in chronic lymphocytic leukemia ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 6, pp. 1744-1755 . https://doi.org/10.1158/1078-0432.CCR-20-4576
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Purpose: Although considerable progress has been made with autologous T cell–based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity tha
Autor:
Hans van Vliet, Paul W. H. I. Parren, Rieneke van de Ven, Jana Vree, Roeland Lameris, Tanja D. de Gruijl, Renate de Boer, Anita G.M. Stam, George L. Scheffer, Arnon P. Kater, Steven T. Pals, Mark-David Levin, Rob C. Roovers, Iris de Weerdt
Publikováno v:
Cancer immunology research, 9(1), 50-61. American Association for Cancer Research Inc.
Cancer Immunology Research, 9(1), 50-61. AMER ASSOC CANCER RESEARCH
de Weerdt, I, Lameris, R, Scheffer, G L, Vree, J, de Boer, R, Stam, A G, van de Ven, R, Levin, M-D, Pals, S T, Roovers, R C, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies ', Cancer Immunology Research, vol. 9, no. 1, pp. 50-61 . https://doi.org/10.1158/2326-6066.CIR-20-0138
Cancer Immunology Research, 9(1), 50-61. American Association for Cancer Research Inc.
Cancer Immunology Research, 9(1), 50-61. AMER ASSOC CANCER RESEARCH
de Weerdt, I, Lameris, R, Scheffer, G L, Vree, J, de Boer, R, Stam, A G, van de Ven, R, Levin, M-D, Pals, S T, Roovers, R C, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies ', Cancer Immunology Research, vol. 9, no. 1, pp. 50-61 . https://doi.org/10.1158/2326-6066.CIR-20-0138
Cancer Immunology Research, 9(1), 50-61. American Association for Cancer Research Inc.
Novel T cell-based therapies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), are thought to have strong potential. Progress, however, has been hampered by low efficacy and high toxicity.
Autor:
Bart, Geboers, Florentine E F, Timmer, Petrousjka M, van den Tol, Tanja D, de Gruijl, Hester J, Scheffer, Martijn R, Meijerink
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 165
Irreversible electroporation (IRE) employs high-voltage electrical pulses for non-thermal image-guided tumor ablation in solid organs. The pulses disrupt the membrane potential of all cells within the ablation zone causing loss of tumour cell homeost
Autor:
Robbert S. Puijk, Rafael V. Davalos, Alette H. Ruarus, Martijn R. Meijerink, Hester J. Scheffer, Bart Geboers, Philip M. Graybill, Sanne Nieuwenhuizen, Petrousjka van den Tol, Boris Rubinsky, Tanja D. de Gruijl, Damijan Miklavčič
Publikováno v:
Geboers, B, Scheffer, H J, Graybill, P M, Ruarus, A H, Nieuwenhuizen, S, Puijk, R S, van den Tol, P M, Davalos, R V, Rubinsky, B, de Gruijl, T D, Miklavčič, D & Meijerink, M R 2020, ' High-Voltage Electrical Pulses in Oncology : Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy ', Radiology, vol. 295, no. 2, pp. 254-272 . https://doi.org/10.1148/radiol.2020192190
This review summarizes the use of high-voltage electrical pulses (HVEPs) in clinical oncology to treat solid tumors with irreversible electroporation (IRE) and electrochemotherapy (ECT). HVEPs increase the membrane permeability of cells, a phenomenon
Autor:
Arjan A. van de Loosdrecht, Tanja D. de Gruijl, Nathalie van Leeuwen-Kerkhoff, Theresia M. Westers, Pino J. Poddighe, Shahram Kordasti
Publikováno v:
Haematologica
van Leeuwen-Kerkhoff, N, Westers, T M, Poddighe, P J, de Gruijl, T D, Kordasti, S & van de Loosdrecht, A A 2020, ' Thrombomodulin expressing monocytes are associated with low risk features in myelodysplastic syndromes and dampen excessive immune activation ', Haematologica, vol. 105, no. 4, pp. 961-970 . https://doi.org/10.3324/haematol.2019.219303
Haematologica, 105(4), 961-970. Ferrata Storti Foundation
van Leeuwen-Kerkhoff, N, Westers, T M, Poddighe, P J, de Gruijl, T D, Kordasti, S & van de Loosdrecht, A A 2020, ' Thrombomodulin expressing monocytes are associated with low risk features in myelodysplastic syndromes and dampen excessive immune activation ', Haematologica, vol. 105, no. 4, pp. 961-970 . https://doi.org/10.3324/haematol.2019.219303
Haematologica, 105(4), 961-970. Ferrata Storti Foundation
The bone marrow of patients with low-risk myelodysplastic syndromes (MDS) is often an inflammatory environment and associated with an active cellular immune response. An active immune response generally contributes to antitumor responses and may prev